September 9, 2021
Dermavant Announces First Patient Dosed in ADORING ...
Read More
August 10, 2021
Dermavant Announces FDA Acceptance for Filing of N ...
Read More
June 7, 2021
Dermavant Announces $200 Million of Financing ...
Read More
June 3, 2021
Dermavant Submits New Drug Application (NDA) to FD ...
Read More
May 6, 2021
Dermavant Announces Appointment of Michael Swartzb ...
Read More
April 16, 2021
Dermavant Announces Tapinarof Data Presentations a ...
Read More
March 25, 2021
FORTUNE Names Dermavant One of the 2021 Best Workp ...
Read More
March 11, 2021
Dermavant Announces Tapinarof Data Presentation at ...
Read More
February 18, 2021
Positive Data from PSOARING 3 Support Long-Term Us ...
Read More
January 21, 2021
Dermavant Announces Tapinarof Data Presentation at ...
Read More
November 17, 2020
Dermavant Named One of Fortune® Magazine’s 2020 ...
Read More
October 27, 2020
Dermavant’s Pivotal Phase 3 PSOARING Data for Ta ...
Read More
October 22, 2020
Dermavant Announces Presentation of Tapinarof Pivo ...
Read More
August 26, 2020
Dermavant Reports Positive Phase 3 Results for Tap ...
Read More
June 16, 2020
Dermavant Announces Publication in JAAD of Seconda ...
Read More
June 9, 2020
Dermavant Completes Patient Enrollment for Long-Te ...
Read More
May 26, 2020
Dermavant Announces Publication in JAAD of Seconda ...
Read More
April 2, 2020
Dermavant Completes Patient Enrollment for Two Pha ...
Read More
January 15, 2020
Dermavant Enters into Exclusive License Agreement ...
Read More
December 3, 2019
Dermavant Announces First Patient Dosed in Phase 2 ...
Read More
